Safety and Immunogenicity of Different Formulations of Norovirus Vaccine Candidate in Healthy Adults: A Randomized, Controlled, Double-Blind Clinical Trial

Geert Leroux-Roels, Jakob P Cramer, Paul M Mendelman, James Sherwood, Ralf Clemens, Annelies Aerssens, Ilse De Coster, Astrid Borkowski, Frank Baehner, Pierre Van Damme, Geert Leroux-Roels, Jakob P Cramer, Paul M Mendelman, James Sherwood, Ralf Clemens, Annelies Aerssens, Ilse De Coster, Astrid Borkowski, Frank Baehner, Pierre Van Damme

Abstract

Background: We investigated safety and immunogenicity of 1-2 doses of different bivalent virus-like particle (VLP) norovirus vaccine candidate (NoV) formulations in healthy 18- to 64-year-olds.

Methods: On days 1 and 28, participants (n = 420) randomized to 14 equal groups received intramuscular control vaccine (hepatitis A) or 1 of 11 NoV formulations containing varying dosages of GI.1 and GII.4c genotype VLP antigens with aluminum hydroxide [Al(OH)3], and 0 μg, 15 μg, or 50 μg monophosphoryl lipid A (MPL). Immunogenicity was assessed on days 1, 28, 56, 208 and 393. Solicited local and systemic reactions were recorded for 7 days, unsolicited adverse events (AEs) until day 56, and serious AEs throughout the trial.

Results: All NoV formulations induced similar increases in pan-immunoglobulin, immunoglobulin A, and histo-blood group binding antigen-blocking antibodies by day 56, mostly after 1 dose, that persisted above baseline to day 393. Higher GI.1 content interfered with GII.4c responses, and responses did not benefit from MPL. Overall reactogenicity consisted of mainly mild injection site pain, headache, and fatigue. No vaccine-related serious AEs were reported.

Conclusions: All candidate NoV formulations were well tolerated. Overall, 15 μg GI.1/50 μg GII.4c elicited the best balance of immunogenicity with no clear benefit of MPL, and is the candidate formulation being taken forward in clinical development.

Clinical trials registration: NCT02038907.

Keywords: adults; immunogenicity; norovirus; reactogenicity; vaccine.

© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America.

Figures

Figure 1.
Figure 1.
Geometric mean titers (95% confidence interval) of pan-immunoglobulin (Pan-Ig) against GI.1 and GII.4c virus-like particle (VLP) antigens. Upper panels show grouping by VLP antigen dosages, irrespective of the inclusion or dosage of monophosphoryl lipid A (MPL) (VLP 15/15 = groups 1, 4, and 7; VLP 15/50 = groups 2, 5, and 8A; VLP 50/50 = groups 3, 6, and 9). Lower panels show grouping by MPL dosage irrespective of VPL composition (0 μg MPL = groups 7, 8A, and 9; 15 μg MPL = groups 4, 5, and 6; 50 μg MPL = groups 1, 2, and 3).
Figure 2.
Figure 2.
Geometric mean (95% confidence interval) of histo-blood group binding antigen (HBGA) antibodies (GMBT50) against GI.1 and GII.4c virus-like particle (VLP) antigens. Upper panels show grouping by VLP antigen dosages, irrespective of the inclusion or dosage of monophosphoryl lipid A (MPL) (VLP 15/15 = groups 1, 4, and 7; VLP 15/50 = groups 2, 5, and 8A; VLP 50/50 = groups 3, 6, and 9). Lower panels show grouping by MPL dosage irrespective of VPL composition (0 μg MPL = groups 7, 8A, and 9; 15 μg MPL = groups 4, 5, and 6; 50 μg MPL = groups 1, 2, and 3).
Figure 3.
Figure 3.
Geometric mean (95% confidence interval) of histo-blood group binding antigen (HBGA) antibodies (GMBT50) against different GII.4 antigens: the GII.4c virus-like particle (VLP) antigen and those from GII.4 Cincinnati 2003 and GII.4 Sydney 2012 strains. Sera tested were from group 5 (n = 30) and group 8A (n = 32), which had received 15 μg monophosphoryl lipid A (MPL) and no MPL, respectively, in formulations with 15 μg GI.1 and 50 μg GII.4c VLP antigen dosages.

References

    1. Foodborne Disease Burden Epidemiology Reference Group 2007–2015. WHO estimates of the global burden of foodborne diseases. . Accessed 3 December 2016.
    1. Vinjé J. Advances in laboratory methods for detection and typing of norovirus. J Clin Microbiol 2015; 53:373–81.
    1. Mattner F, Sohr D, Heim A, Gastmeier P, Vennema H, Koopmans M. Risk groups for clinical complications of norovirus infections: an outbreak investigation. Clin Microbiol Infect 2006; 12:69–74.
    1. Trivedi TK, Desai R, Hall AJ, Patel M, Parashar UD, Lopman BA. Clinical characteristics of norovirus-associated deaths: a systematic literature review. Am J Infect Control 2013; 41:654–7.
    1. Adler JL, Zickl R. Winter vomiting disease. J Infect Dis 1969; 119:668–73.
    1. White PA. Evolution of norovirus. Clin Microbiol Infect 2014; 20:741–5.
    1. Atmar RL, Bernstein DI, Harro CD et al. . Norovirus vaccine against experimental human Norwalk virus illness. N Engl J Med 2011; 365:2178–87.
    1. Bernstein DI, Atmar RL, Lyon GM et al. . Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults. J Infect Dis 2015; 211:870–8.
    1. Lindesmith LC, Donaldson E, Leon J et al. . Heterotypic humoral and cellular immune responses following Norwalk virus infection. J Virol 2010; 84:1800–15.
    1. Parra GI, Bok K, Taylor R et al. . Immunogenicity and specificity of norovirus consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations. Vaccine 2012; 30:3580–6.
    1. El-Kamary SS, Pasetti MF, Mendelman PM et al. . Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J Infect Dis 2010; 202:1649–58.
    1. Treanor JJ, Atmar RL, Frey SE et al. . A novel intramuscular bivalent norovirus virus-like particle vaccine candidate—reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults. J Infect Dis 2014; 210:1763–71.
    1. Atmar RL, Baehner F, Cramer JP, Song E, Borkowski A, Mendelman PM; NOR-201 Study Group Rapid responses to 2 virus-like particle norovirus vaccine candidate formulations in healthy adults: a randomized controlled trial. J Infect Dis 2016; 214:845–53.
    1. Reeck A, Kavanagh O, Estes MK et al. . Serological correlate of protection against norovirus-induced gastroenteritis. J Infect Dis 2010; 202:1212–8.
    1. Atmar RL, Bernstein DI, Lyon GM et al. . Serological correlates of protection against a GII.4 norovirus. Clin Vaccine Immunol 2015; 22:923–9.
    1. de Graaf M, van Beek J, Koopmans MP. Human norovirus transmission and evolution in a changing world. Nat Rev Microbiol 2016; 14:421–33.
    1. Szarewski A. HPV vaccine: Cervarix. Expert Opin Biol Ther 2010; 10:477–87.
    1. Beran J. Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients. Expert Opin Biol Ther 2008; 8:235–47.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren